Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.
NIOX Group plc has announced the timetable for its proposed final dividend for the financial year ended 31 December 2025, set at 1.55 pence per share. The company continues to return cash to shareholders in line with its capital allocation policy, underlining its confidence in ongoing cash generation.
The shares will trade ex-dividend on 21 May 2026, with a record date of 22 May 2026 and payment scheduled for 22 June 2026. The payout remains contingent on shareholder approval at the annual general meeting on 21 May 2026, highlighting standard governance steps before the distribution is finalized.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on NIOX Stock
According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.
The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.
To see Spark’s full report on NIOX stock, click here.
More about Circassia Pharmaceuticals
NIOX Group plc is a UK-based medical diagnostics company listed on AIM, focused on products for measuring airway inflammation. Its core offering supports clinicians in diagnosing and managing respiratory conditions, positioning the group within the broader respiratory healthcare and diagnostics market.
Average Trading Volume: 704,070
Technical Sentiment Signal: Buy
Current Market Cap: £271.6M
For detailed information about NIOX stock, go to TipRanks’ Stock Analysis page.